CommercialPrior AuthMedium impact
08.02.27a, Tarlatamab-dlle (Imdelltra®) for intravenous use
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jun 15, 2026
We identified it
Jun 19, 2026
Summary
New medical necessity criteria have been established for Tarlatamab-dlle (Imdelltra®) intravenous therapy, a specialty pharmacy medication. This policy defines coverage requirements and approval criteria for this drug treatment.
Action Required
Before June 15, 2026: Billing team must review and implement new medical necessity criteria for Tarlatamab-dlle (Imdelltra®) prior authorizations. Update prior authorization request forms to include required documentation elements. Notify providers about new coverage criteria to ensure proper documentation for approval.